+

WO2013023014A1 - Système et procédé de détermination d'une quantité d'insuline à administrer à un patient diabétique - Google Patents

Système et procédé de détermination d'une quantité d'insuline à administrer à un patient diabétique Download PDF

Info

Publication number
WO2013023014A1
WO2013023014A1 PCT/US2012/050061 US2012050061W WO2013023014A1 WO 2013023014 A1 WO2013023014 A1 WO 2013023014A1 US 2012050061 W US2012050061 W US 2012050061W WO 2013023014 A1 WO2013023014 A1 WO 2013023014A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
user
basal
activity
controller
Prior art date
Application number
PCT/US2012/050061
Other languages
English (en)
Inventor
Cliff SCHERB
Original Assignee
Scherb Cliff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherb Cliff filed Critical Scherb Cliff
Publication of WO2013023014A1 publication Critical patent/WO2013023014A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M2005/14208—Pressure infusion, e.g. using pumps with a programmable infusion control system, characterised by the infusion program
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure

Definitions

  • Diabetes is a disease in which the pancreas fails to properly function to produce insulin. Insulin allows the body to break down blood sugar. There are three primary types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. In type 1 diabetes, the body fails to produce insulin. In type 2, the body's cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency. Gestational diabetes is a temporal diabetic condition of high blood glucose levels during pregnancy. Both type 1 and type 2 diabetes are chronic conditions that cannot be cured. All forms of diabetes have been treatable, in some sense, since insulin became available in 1921. While type 2 diabetes may be controlled with medications and diet, treatment with insulin is the only effective treatment for individuals with type 1 diabetes, and is often ultimately required by individuals with type 2 diabetes.
  • a system that provides a novel manner of determining and providing administration of insulin to a diabetic individual.
  • the system and method accommodate the insulin needs of a diabetic individual, from at rest to any level of activity.
  • the system may include (i) a software program stored and executed in association with a microprocessor, the software program providing for an individual to input data for predetermined parameters and, based upon such input data, the program determining a rate of administration of insulin for the individual, (ii) an insulin pump having a controller which based upon individual input data for the predetermined parameters, activates the pump to meter a determined dosage of rapid release insulin the user; i.e., at a determined relatively steady rate of administration or at bolus amounts, and (iii) an implantable or externally provided artificial pancreas including an insulin pump, a continuous glucose monitor, and a controller which based upon an individual's input data for predetermined parameters and the feedback of blood glucose data from the glucose monitor, activates the pump to meter a determined dosage of rapid release insulin to the user; i.e., at a determined relatively steady rate of administration or at bolus amounts.
  • the system is controlled by software instructions used in association with a microprocessor.
  • a user interface is provided so that the user can interact with the controller to provide input data and select amongst various presets. More particularly, the user interface allows the user to input user data, including set-up information that personalizes the system to the needs of the user, to establish or select routines for insulin administration based on defined levels of activity, as well as interact with the controller on an ongoing basis to enter data relevant to modifying the routines based upon parameters discussed below.
  • the controller includes a setup routine in which (1) the daily at rest insulin needs (in units of rapid release insulin) for an individual (a user of the system) is established, (2) the number of grams of carbohydrate consumption that is covered by one unit of insulin for that individual is established, (3) and a total insulin to carbohydrate (I:C) ratio for the individual is calculated.
  • the controller also implements a method in which (4) the daily basal insulin rates for various times over the curse of a day based on a cumulative level of activity over a rolling predetermined period, such as a rolling seven day period, is determined and (5) a bolus insulin need relative to the daily basal insulin need is determined in order to maintain the I:C ratio substantially constant, regardless of the level of individual activity.
  • the system calculates an adjustment to the total daily basal insulin needs based on the cumulative number of hours of activity during the prior rolling predetermined period; i.e., a rolling daily basal need of insulin. With increased activity over the rolling predetermined period, the rolling daily basal need relative to an at-rest basal need is decreased. Further in accord with one aspect of the invention, the rolling daily basal need is not infused evenly throughout the day. Rather, in view of different insulin needs at different times of a day, e.g., due to early morning increases in blood sugar ("dawn phenomenon") and hormonal changes throughout the day, the rolling daily basal need is metered to the individual at various rates throughout the day, rather than a constant rate.
  • the percentage of insulin provided by bolus infusion increases as the percentage provided by basal infusion decreases.
  • the bolus infusion in distinction from the 'background' basal levels, is administered anytime carbohydrates are consumed, as well as provide a route to correction for high blood sugars.
  • modified exercise basal rates are provided based on the activity level of an exercise.
  • the activity level may be determined, e.g., by a predetermined attribution of a level of exertion for a given time of exercise at a given exertion level, by a user-indicated level of exertion for one or more time periods over the course of the exercise, or for a monitored/measured heart rate over the course of the exercise.
  • exercise recovery basal rates are provided post-exercise. Based on the duration and intensity of the exercise, a temporary recovery basal rate is selected by the system.
  • the preferred parameter to determine the recovery basal rate is heart rate, which can be obtained through real-time monitoring, or in the absence of heart rate monitoring, user perceived exertion.
  • Fig. 1 is a schematic diagram of an insulin pump system according to the invention.
  • Fig. 2 is a flow diagram of the set-up procedure for a user at the controller of the system.
  • Fig. 3 is a chart illustrating information input, calculated, and/or stored at the controller during the set-up procedure.
  • Fig. 4 is a flow diagram of the calculation by the controller of the adjusted rolling basal rates.
  • Fig. 5 A is a chart illustrating the relationship of basal and bolus insulin as a percentage of total insulin needs as a user's activity level increases over the rolling period.
  • Fig. 5B is exemplar user data indicating the relationship of basal and bolus insulin as a percentage of total insulin needs as a user's activity level increases over the rolling period.
  • Fig. 6 is a chart illustrating the relationship of the different rates at which rolling basal insulin is administered at different time ranges over a day depending on user's activity level over the rolling period.
  • Fig. 8 is a flow diagram illustrating how post-exercise recovery basal rates are calculated.
  • Fig. 9 is a chart of data for an exemplar user for any activity between inactivity through 24 hours activity in a rolling period, including adjusted rolling basal rates for time ranges throughout a day as well as various other data.
  • Figs. 10 - 14 provide data in chart form for adjusted basal rates for an exemplar user undertaking an exercise training schedule, in which Fig. 10 provides initial rolling basal rates, Fig. 11 provides recommended carbohydrate intake, Fig. 12 indicates the grams of carbohydrate to consume at different times during an exercise routine, Fig. 13 sets out post-exercise recovery basal rates, and Fig. 14 provides an updated set of rolling basal rates which is updated based on the current level of activity in the rolling period.
  • the term 'database' means one or more structured sets of persistent data associated with software to update and/or query the persistent data.
  • the controller 14 includes a processing platform 30 having a central processing unit (CPU), a memory system, and input/output interfaces.
  • the processing platform 30 is provided with software 32, including database management logic and application logic.
  • the processing platform 30 is coupled to non-volatile storage 34, which contains the software 32 and one or more databases.
  • the software 32 is loaded from non-volatile storage 34 to the processing platform 30 for execution on the processing platform 30.
  • the application logic and database management logic of the software 32 cooperate to access the one or more databases stored in the non-volatile storage 34 in order to carry out the control methodologies described herein in detail.
  • the controller 14 includes input devices 36 such as buttons, scroll wheel, knobs, keypad, microphone, and/or any other device suitable for data input to the controller 14.
  • the controller 14 also includes a display screen 38 and optionally a speaker 40 to provide visual as well as audio information to the user. Other output devices to present information to the user may be provided as well.
  • a communication interface 42 is provided for
  • the interface 42 is preferably a wireless network interface, but may be a wired network interface.
  • the system is preferably provided with the appropriate interface(s) to allow firmware and/or database updates.
  • the system 10 may include additional input devices to monitor other pertinent physiological parameters.
  • the system may include a heart rate monitor 46 with a network interface 48 that preferably wirelessly communicates measured heart rate to the controller 14.
  • the measured or input heart rate of a user can be used to modify insulin rates for the user.
  • the system may similarly include a pedometer that communicates its activity to the controller 14. As discussed below, such activity monitors can be used to modify insulin rates for the user.
  • a set-up routine is performed at the controller 14 to personalize the system 10 for the particular user of the system.
  • the set-up routine allows the controller 14 to determine or select a set of baseline basal insulin rates for the user from a set of basal rates in a database in the memory storage 34.
  • the set-up routine includes determining (1) the daily 'at rest' insulin needs (in units of rapid release insulin) for the user 102, (2) the number of grams of carbohydrate consumption that is covered by one unit of rapid release insulin for the user at 106, and (3) a total desirable insulin to carbohydrate (I:C) ratio for the user at 110.
  • an additional part of the set-up includes establishing an initial cumulative activity level for the user over a predetermined rolling period and establishing a corresponding rolling period basal need and corresponding daily basal rates.
  • the daily 'at rest' insulin needs for a particular diabetic individual is preferably established at 102 from reference to data obtained from reliable reference material and is commonly based on such factors as age, gender, height, and weight of an individual, as indicated at 104.
  • a tool to determine daily 'at rest' insulin needs is available from diabetesnet.com at www.diabetesnet.corn/diabetes_tools/tools_tdd.php and such tool uses suitable reference data.
  • the memory storage 34 preferably includes databases that similarly relate such factors or others to a daily 'at rest' insulin need.
  • a daily 'at rest' insulin need (e.g., 40.8 units), shown at 120, is determined for a user, and from the total insulin need, the total 'at rest' basal insulin needs (e.g., 23.3 units— not shown) as well as an average 'at rest' basal rate (e.g., 0.97 units/hour) shown at 122 are read, calculated or otherwise determined from data in the corresponding database.
  • the number of grams of carbohydrates covered by one unit of rapid release insulin for the user is obtained at 124 based on the 'set-up' factors from the corresponding database at 108 in Fig. 2.
  • the number of grams of carbohydrates covered by one unit of rapid release insulin is used to calculate an insulin to carbohydrate (I:C) ratio.
  • I:C insulin to carbohydrate
  • the I:C ratio is 1/22 or 0.052 as shown at 126.
  • Data for the entire potential user population of the system is preferably stored in databases in the non-volatile memory 34 in the controller for access during the set-up routine.
  • the user inputs at 130 the cumulative number of hours of activity the user has undertaken during a current rolling period of predetermined length.
  • the preferred rolling period is a 7-day period or week.
  • the user uses the preferred rolling 7-day period, the user inputs the cumulative number of hours of activity (i.e., exercise) undertaken during the current 7-day period.
  • the user inputs an exact number of hours of activity, preferably ranging from 0 to 24 over the rolling period.
  • additional 'low activity' activity settings may be input or selected.
  • a first low-level activity setting is designated AA and corresponds to bed rest at a basal metabolic rate.
  • a second low-level activity setting is designated AB and corresponds to substantially complete rest with no more that 10 minutes of total movement a day.
  • a third low-level activity setting is designated AC and corresponds to a resting state more active than AB but of no more than 30 minutes of daily movement. Then, the '0' hour of activity corresponds to more movement than AC but preferably no more than 90 minutes of daily movement, but not necessarily movement considered exercise.
  • Fig. 5A is a chart illustrating the manner in which the basal need decreases as a proportion of overall daily insulin need, and that consequently the bolus insulin
  • Fig. 5B provides data for an exemplar user having total daily 'at rest' insulin needs of 31.1 units and an I:C ratio of 0.052.
  • the relationship of the basal to bolus insulin needs corresponds to the relationship shown in Fig. 5A. It is recognized that fewer or additional low-level activity settings may be provided, or the controller may permit input of activity in minutes or other portion of an hour over the rolling period where the user is not active for at least one hour.
  • the system determines an adjustment relative to the daily total 'at rest' basal insulin need (from step 120) and the average 'at rest' basal rate (from step 122) to determine a rolling daily basal insulin need at 132 and an average rolling daily basal insulin rate at 134. That is, referring again to the chart of Fig. 5 A, it has been determined with increased activity over the rolling period, the rolling daily basal insulin need relative to an 'at rest' basal insulin need is decreased.
  • the processing platform 30 carries out the calculation(s) necessary to effect the adjustment to determine the rolling daily basal insulin need.
  • the rolling daily basal insulin need is determined (as a percentage of the total insulin need)
  • the average rolling basal insulin rate per hour is optionally calculated at 134 as the rolling basal insulin need divided by 24 hours.
  • range 1 corresponds to 'sleep'
  • range 2 corresponds to 'waking time and dawn phenomenon'
  • range 3 corresponds 'daytime active hours'
  • range 4 corresponds to 'early evening hours'. It is appreciated that a different number of ranges could be used (fewer or more), and that the times of day during which each range starts can be specifically tailored to the user's daily habits (waking time, active hours, sleep time, etc.).
  • the amount of activity throughout a day is preferably recorded at 138.
  • the amount of activity throughout a day can be recorded, by way of examples only, (i) at the end of each day by manual user input to the controller, (ii) more preferably by manual user input to the controller throughout each day, e.g., at the conclusion of each and every activity, and/or (iii) even more preferably automatically via controller interface with, e.g., a heart rate monitor 46, pedometer, etc.
  • the rolling seven day basal recovery rate post-workout uses the end of the most recent workout as its timed starting point. For each subsequent two hours of time that passes post-workout the basal rate will drop by one basal rate level; that is, two hours post-activity the basal rate will drop from A15 to A14, and again two hours later from A14 to A13. This is in contrast to moving up basal rates by only one basal rate per hour of increased cumulative activity on a rolling seven day basis.
  • the databases may be upgradeable by the user (e.g., via a USB or other data cable or a wireless connection connecting the controller to a computer and/or dedicated web site) to allow the controller to have a relatively current list of commercially available foods, specialty foods, ethnic foods, foods specific to a dieting program, foods specific to athletic training, etc.
  • a recommended corresponding number of units of insulin to bolus is output. This recommended number of units to bolus can then be accepted at 158 or overridden at 160 by the user. If the number of units is overridden by the user, a warning may be displayed to the user (and optionally an audible warning tone) which the user can subsequently override. If the user does not accept or override, the controller enters a ready state at 162 to again track
  • Zone 1 is preferably set at not exceeding 85 % of the lactate threshold heart rate and generally corresponds to very low level of exercise, such as an easy walk or hike.
  • Zone 1 may be scored as a perceived exertion (PE) of between 1 - 3 on a scale of 1 - 10. It has been determined that insulin sensitivity is 2.0 - 3.5 times greater than at non-activity during this level of activity. Further, the post-exercise basal insulin rate is reduced by 30% - 70%) (i.e., is set at 70%> - 30%> of the rolling basal rate) during the post-activity insulin sensitivity period.
  • PE perceived exertion
  • the basal rate level will drop by one basal level for every two hours. Assuming the user will not exercise again, the user would reach B0 after 20 hours of inactivity. The system automatically accommodates the change in basal level and basal rates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Primary Health Care (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Signal Processing (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un système qui détermine les besoins en insuline d'un individu diabétique, du repos jusqu'à un quelconque niveau d'activité, et administre l'insuline à l'individu. Le système inclut une pompe et une unité de commande pour la pompe. L'unité de commande inclut une interface utilisateur qui permet à l'utilisateur d'entrer des données d'utilisateur, y compris des informations de réglage qui personnalisent le système selon les besoins de l'utilisateur, d'établir ou de sélectionner des routines d'administration de l'insuline basées sur des niveaux définis d'activité, ainsi que d'interagir avec l'unité de commande sur une base continue pour entrer des données pertinentes en vue modifier les routines basées sur des paramètres.
PCT/US2012/050061 2011-08-11 2012-08-09 Système et procédé de détermination d'une quantité d'insuline à administrer à un patient diabétique WO2013023014A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161522514P 2011-08-11 2011-08-11
US61/522,514 2011-08-11
US201261594557P 2012-02-03 2012-02-03
US61/594,557 2012-02-03

Publications (1)

Publication Number Publication Date
WO2013023014A1 true WO2013023014A1 (fr) 2013-02-14

Family

ID=47668940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/050061 WO2013023014A1 (fr) 2011-08-11 2012-08-09 Système et procédé de détermination d'une quantité d'insuline à administrer à un patient diabétique

Country Status (1)

Country Link
WO (1) WO2013023014A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138171A1 (fr) * 2019-12-30 2021-07-08 Roche Diabetes Care, Inc. Procédés de gestion du diabète mis en oeuvre par ordinateur
US20220193338A1 (en) * 2020-12-23 2022-06-23 Dexcom, Inc. Bolus advisor with correction boluses based on risk, carb-free bolus recommender, and meal acknowledgement

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228681A1 (en) * 2005-04-06 2006-10-12 Clarke Mark A Automated processing of training data
US20070112298A1 (en) * 2005-11-17 2007-05-17 Medtronic Minimed, Inc. External infusion device with programmable capabilities to time-shift basal insulin and method of using the same
US20080172026A1 (en) * 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having a suspension bolus
US20080194922A1 (en) * 2005-09-07 2008-08-14 Holden James F Potentiation for medical therapies
US20080228056A1 (en) * 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US20100185175A1 (en) * 2006-02-09 2010-07-22 Deka Products Limited Partnership Systems and methods for fluid delivery
US20100262434A1 (en) * 2007-12-13 2010-10-14 Shaya Steven A Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose
WO2011039741A1 (fr) * 2009-09-30 2011-04-07 Mor Research Applications Ltd. Dispositif de surveillance pour la gestion de l'administration d'insuline
US20110098548A1 (en) * 2009-10-22 2011-04-28 Abbott Diabetes Care Inc. Methods for modeling insulin therapy requirements

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228681A1 (en) * 2005-04-06 2006-10-12 Clarke Mark A Automated processing of training data
US20080194922A1 (en) * 2005-09-07 2008-08-14 Holden James F Potentiation for medical therapies
US20070112298A1 (en) * 2005-11-17 2007-05-17 Medtronic Minimed, Inc. External infusion device with programmable capabilities to time-shift basal insulin and method of using the same
US20100185175A1 (en) * 2006-02-09 2010-07-22 Deka Products Limited Partnership Systems and methods for fluid delivery
US20080172026A1 (en) * 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having a suspension bolus
US20080228056A1 (en) * 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US20100262434A1 (en) * 2007-12-13 2010-10-14 Shaya Steven A Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose
WO2011039741A1 (fr) * 2009-09-30 2011-04-07 Mor Research Applications Ltd. Dispositif de surveillance pour la gestion de l'administration d'insuline
US20110098548A1 (en) * 2009-10-22 2011-04-28 Abbott Diabetes Care Inc. Methods for modeling insulin therapy requirements

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021138171A1 (fr) * 2019-12-30 2021-07-08 Roche Diabetes Care, Inc. Procédés de gestion du diabète mis en oeuvre par ordinateur
EP4084687A1 (fr) * 2019-12-30 2022-11-09 F. Hoffmann-La Roche AG Procédés de gestion du diabète mis en oeuvre par ordinateur
JP7620633B2 (ja) 2019-12-30 2025-01-23 エフ ホフマン－ラ ロッシュ アクチェン ゲゼルシャフト コンピュータで実現される糖尿病管理方法
US20220193338A1 (en) * 2020-12-23 2022-06-23 Dexcom, Inc. Bolus advisor with correction boluses based on risk, carb-free bolus recommender, and meal acknowledgement

Similar Documents

Publication Publication Date Title
EP2232393B1 (fr) Maintien du contrôle glycémique durant l'exercice
US20250025631A1 (en) Open-loop insulin delivery basal parameters based on insulin delivery records
US11576594B2 (en) Insulin pump based expert system
US8945085B2 (en) Method and device for calculating a bolus amount
US20190328967A1 (en) Expert system for insulin pump therapy
CN114760918A (zh) 血糖控制系统
JP2023022020A (ja) インスリン・デリバリ量の調節
EP3721921A1 (fr) Procédé et système faisant appel à des mégadonnées en nuage, destinés à une optimisation de la configuration individualisée de pompe à insuline
CA2471007C (fr) Systeme d'administration de medicaments et appareil de controle associe
US8088098B2 (en) Tailored basal insulin delivery system and method
EP2596448B1 (fr) Système et procédé examinant l'effet de l'activité physique sur le système gluco-régulateur
US20080206799A1 (en) Carbohydrate ratio testing using frequent blood glucose input
EP2023256A1 (fr) Surveillance de l'administration de médicaments
EP3742449B1 (fr) Système et procédé pour intégrer un exercice dans le traitement du diabète en boucle fermée
EP3926638A1 (fr) Gestion de l'insuline
JP2010521222A (ja) 血糖入力を使用する基礎速度試験
WO2009086216A1 (fr) Procédé et appareil pour fournir une gestion de profil de traitement
JP2006175227A (ja) 糖尿病管理装置
US20150352280A1 (en) Insulin pump apparatus, device, methodology and kit
US20170177818A1 (en) Exercise as a Drug
US20080214905A1 (en) System and Method for Preventing Hypoglycaemia in a Human Type 1 Diabetic Patient During Physical Activity
WO2013023014A1 (fr) Système et procédé de détermination d'une quantité d'insuline à administrer à un patient diabétique
EP2888684B1 (fr) Pompe à insuline et ses procédés de fonctionnement
WO2017087192A1 (fr) Pompes et systèmes de perfusion médicale
EP4336510A1 (fr) Système et procédé d'ajustement de l'administration d'insuline pour prendre en compte la résistance à l'insuline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12821673

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12821673

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载